source
- Atara and Pierre Fabre resubmit Ebvallo cell therapy after second FDA rejectionAtara Biotherapeutics and Pierre Fabre Pharmaceuticals have filed a new FDA submission for their cell therapy candidate Ebvallo (tabelecleucel), aimed at treating Epstein‑Barr virus‑positive post‑t…
- FDA launches nationwide recruitment to broaden scientific and consumer representation on advisory committeesThe U.S. Food and Drug Administration announced a new nationwide effort to recruit qualified experts and consumer representatives for its advisory committees. The agency issued two Federal Register…